Pulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET
Company Participants
Dorothy Morgan - Investor Relations, Gilmartin Group LLC
Glendon French - President and Chief Executive Officer
John McKune - Interim Chief Financial Officer and Vice President Corporate Controller
Conference Call Participants
Jason Bednar - Piper Sandler
Frederick Wise - Stifel Financial Corp.
Larry Biegelsen - Wells Fargo
Joanne Wuensch - Citi
Jon Young - Canaccord
Alex Nowak - Craig-Hallum
Operator
Thank you for standing by. Welcome to the Pulmonx Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. As a reminder, today’s conference is being recorded.
I would now like to turn the conference over to your host, Laine Morgan at the Gilmartin Group. Laine, please go ahead.
Dorothy Morgan
Thank you, operator. Good afternoon and thank you all for participating in today’s call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer, and John McKune, Interim Chief Financial Officer and Vice President Corporate Controller. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of the press release is available on Pulmonx’s website.
Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
All forward-looking statements, including without limitation those relating to our Chief Financial Officer transition, our operating trends, commercial strategies and future financial performance; the timing and results of clinical trials; expense management, expectations for hiring; growth in our organization; market opportunity; guidance for revenue; gross margin and operating expenses; commercial expansion and product pipeline for development, are based upon our current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our filings with the Securities and Exchange Commission included in quarterly report on Form 10-Q filed with the SEC on August 4, 2023.